Cannabis and Mental Health: It’s Not Just About ‘Cannabis’
A Harvard-affiliated narrative review argues that psychiatric outcomes from cannabis use depend heavily on which cannabinoids are consumed, in what dose and frequency, by whom, and through what route of administration, making broad generalizations about “cannabis” clinically misleading and scientifically inadequate.
Why This Matters
Cannabis legalization is expanding globally while medical cannabis prescriptions are rising sharply, yet public health messaging and clinical guidance still tend to treat “cannabis” as a single exposure. This matters because the psychiatric risk profile of a high-THC concentrate used daily by a teenager bears almost no resemblance to that of a CBD-dominant oral preparation used intermittently by a middle-aged adult. Clinicians need frameworks that move beyond binary thinking about cannabis harm or benefit, and this review attempts to provide one at a moment when the gap between product diversity and evidence clarity is widening rapidly.
Clinical Summary
Cannabis use and mental health have been debated for decades, but the conversation has been muddied by a persistent failure to distinguish between cannabinoids, use patterns, and individual vulnerability factors. In this 2025 Current Opinion article published in CNS Drugs, Kelly Sagar and Staci Gruber of McLean Hospital and Harvard Medical School synthesize existing literature across four psychiatric domains: psychosis, anxiety, mood disorders, and PTSD. Their central argument is mechanistic and pharmacological. Delta-9-THC, the primary intoxicant in cannabis, acts as a partial agonist at CB1 receptors and is responsible for most documented psychiatric harms, including psychotomimetic effects, dose-dependent anxiogenesis, and disruption of neurodevelopmental processes in youth. CBD, by contrast, operates through different pathways and shows early signals of antipsychotic and anxiolytic properties.
The review reports that most negative psychiatric associations in the epidemiological literature track with THC exposure specifically, not cannabis broadly. CBD has shown preliminary promise in small clinical trials for psychosis and anxiety, though the evidence base remains limited. THC’s effects on anxiety appear biphasic, with lower doses potentially anxiolytic and higher doses clearly anxiogenic, though clinical data on low-dose benefits are mixed. Youth and individuals with genetic or familial liability for psychotic disorders face disproportionate risk. Critically, the authors emphasize that cannabis use is not established as a sufficient cause of psychotic disorders but rather as a contributing factor within a multifactorial model. They acknowledge that most observational studies fail to characterize product type, cannabinoid profile, frequency, and route of administration, limiting the interpretability of the existing literature. The authors call for more granular, longitudinal research before clinical recommendations can be refined.
Dr. Caplan’s Take
This review articulates something I find myself explaining to patients constantly: “cannabis” is not one thing, and asking whether it is good or bad for mental health is like asking whether “medication” is good or bad for your body. The framework here, distinguishing THC from CBD, dose from frequency, and youth from adults, is clinically useful and overdue in mainstream discourse. Where I would urge caution is in the enthusiasm around CBD as a psychiatric treatment. The preclinical signals are interesting, but we are far from having the kind of dose-finding, long-term safety, and head-to-head comparison data that would justify recommending CBD as an antipsychotic or anxiolytic outside of a research context.
In practice, what I do with patients who ask about cannabis and mental health is focus on risk stratification. If someone is under 25, has a family history of psychosis, or is using high-potency THC products frequently, I am direct about the evidence of harm. For patients already using cannabis who have stable mental health, I focus on product composition, dose discipline, and monitoring. I do not prescribe CBD for psychiatric indications based on current evidence, but I also do not dismiss patients who report subjective benefit. The honest answer right now is that we need better data, and patients deserve to hear that clearly.
Clinical Perspective
This review sits at a relatively early point in the research arc for precision cannabinoid medicine. Its greatest contribution is conceptual rather than empirical: it offers a structured way of thinking about cannabis exposure variables that most epidemiological studies fail to capture. The evidence it summarizes confirms that THC is the primary driver of psychiatric risk, that youth are a vulnerable population, and that psychosis etiology is multifactorial. It does not, however, establish therapeutic thresholds for CBD, identify reliable biomarkers for individual risk, or resolve the question of whether cannabis use in genetically vulnerable individuals is causal or reflects shared liability. Clinicians should not use this review to justify CBD prescribing for psychiatric conditions, nor should they dismiss its framing of differential cannabinoid risk.
From a pharmacological and safety standpoint, clinicians should be aware that CBD inhibits several cytochrome P450 enzymes, including CYP3A4 and CYP2C19, creating meaningful drug interaction potential with SSRIs, benzodiazepines, antipsychotics, and antiepileptics. High-potency THC products carry dose-dependent risks for acute psychotic symptoms and panic responses, particularly in cannabis-naive patients. The single most actionable recommendation from this review is to begin asking patients not just whether they use cannabis, but what they use, how much, how often, and through what route, because those variables determine the risk profile far more than the binary of use versus nonuse.
Study at a Glance
- Study Type
- Current Opinion / Narrative Review
- Population
- General population, youth, and psychiatric populations (preclinical through epidemiological studies)
- Intervention
- Cannabis exposure, with focus on delta-9-THC and CBD as distinct compounds
- Comparator
- Not applicable (narrative synthesis, no standardized comparator)
- Primary Outcomes
- Psychosis risk, anxiety, mood disorders, and PTSD symptomatology
- Sample Size
- Not applicable (review article; largest cited study N=25,747)
- Journal
- CNS Drugs
- Year
- 2025
- DOI
- 10.1007/s40263-024-01148-2
- Funding Source
- Not reported
What Kind of Evidence Is This
This is an invited Current Opinion article, a form of expert narrative review that does not follow systematic review methodology. It sits below systematic reviews and meta-analyses in the evidence hierarchy and well below randomized controlled trials for questions of therapeutic efficacy. Its most important inference constraint is that without a reproducible search strategy or formal quality assessment of cited studies, the reader cannot determine whether the literature coverage is comprehensive and balanced or reflects selective citation aligned with the authors’ existing positions.
How This Fits With the Broader Literature
The review’s core claims are largely consistent with prior systematic work. The association between high-potency THC use and psychosis risk has been supported by large studies including the EU-GEI case-control study by Di Forti and colleagues (2019), which found that daily use of high-potency cannabis was associated with significantly increased odds of first-episode psychosis. The multifactorial model of psychosis etiology aligns with consensus positions from the National Academies of Sciences (2017) and subsequent Lancet Psychiatry reviews. Where this article extends the conversation is in its explicit framing of CBD as a counterweight to THC-associated harms, drawing on the work of McGuire et al. (2018) showing CBD augmentation in treatment-resistant schizophrenia. However, that trial was small and has not been robustly replicated, and the broader CBD-for-anxiety literature remains dominated by preclinical and uncontrolled human studies.
Common Misreadings
The most likely overinterpretation is to read this review as establishing that CBD is an effective psychiatric treatment and that only THC is harmful. The review does not support either conclusion at the level of clinical evidence. CBD’s therapeutic signals are preliminary, derived largely from preclinical models and small trials with short follow-up. Likewise, while the framing of THC as the primary risk driver is well supported, it should not be taken to mean that CBD-dominant products carry zero psychiatric risk, as evidence on long-term, high-dose CBD use is sparse. The review’s nuanced framing of multifactorial causation in psychosis should also not be misread as dismissing the contribution of cannabis to psychosis onset in vulnerable individuals.
Bottom Line
This narrative review provides a useful conceptual framework for thinking about cannabis and mental health in terms of specific cannabinoids, use patterns, and individual risk factors rather than as a monolithic exposure. It does not generate new evidence or establish clinical thresholds. Its practical value lies in reinforcing that clinicians should assess cannabis use with granularity and that broad claims about cannabis harm or benefit are almost always oversimplifications of a far more complex pharmacological and epidemiological reality.
References
- Sagar KA, Gruber SA. Cannabis and mental health: it’s not just about “cannabis.” CNS Drugs. 2025. DOI: 10.1007/s40263-024-01148-2.
- Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427-436. DOI: 10.1016/S2215-0366(19)30048-3.
- McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 2018;175(3):225-231. DOI: 10.1176/appi.ajp.2017.17030325.
- National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: The National Academies Press; 2017. DOI: 10.17226/24625.
Have thoughts on this? Share it:
